Mans Broekgaarden

Dr. Mans Broekgaarden

Institute for Advanced Biosciences
+2
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
MHMichal Heger
Michal Heger
RGRowan F. van Golen
Rowan F. van Golen
Mans BroekgaardenMans Broekgaarden
Mans Broekgaarden
MMMartin C. Michel
Martin C. Michel
This review addresses the oncopharmacological properties of curcumin at the molecular level. First, the interactions between curcumin and its molecular targets are addressed on the basis of curcumin’s distinct chemical properties, which include H-bond donating and accepting capacity of the β-dicarbonyl moiety and the phenylic hydroxyl groups, H-bond accepting capacity of the methoxy ethers, multivalent metal and nonmetal cation binding properties, high partition coefficient, rotamerization around multiple C–C bonds, and the ability to act as a Michael acceptor. Next, the in vitro chemical stability of curcumin is elaborated in the context of its susceptibility to photochemical and chemical modification and degradation (e.g., alkaline hydrolysis). Specific modification and degradatory pathways are provided, which mainly entail radical-based intermediates, and the in vitro catabolites are identified. The implications of curcumin’s (photo)chemical instability are addressed in light of pharmaceutical curcumin preparations, the use of curcumin analogues, and implementation of nanoparticulate drug delivery systems. Furthermore, the pharmacokinetics of curcumin and its most important degradation products are detailed in light of curcumin’s poor bioavailability. Particular emphasis is placed on xenobiotic phase I and II metabolism as well as excretion of curcumin in the intestines (first pass), the liver (second pass), and other organs in addition to the pharmacokinetics of curcumin metabolites and their systemic clearance. Lastly, a summary is provided of the clinical pharmacodynamics of curcumin followed by a detailed account of curcumin’s direct molecular targets, whereby the phenotypical/biological changes induced in cancer cells upon completion of the curcumin-triggered signaling cascade(s) are addressed in the framework of the hallmarks of cancer. The direct molecular targets include the ErbB family of receptors, protein kinase C, enzymes involved in prostaglandin synthesis, vitamin D receptor, and DNA.

29 October 2015 in Cancer and Metastasis Reviews
Verified
Journal Article
Open access
PDF file
Mans BroekgaardenMans Broekgaarden
Mans Broekgaarden
RWRuud Weijer
Ruud Weijer
TGThomas M. van Gulik
Thomas M. van Gulik
Michael R. HamblinMichael R. Hamblin
Michael R. Hamblin
MHMichal Heger
Michal Heger
Photodynamic therapy (PDT) has emerged as a promising alternative to conventional cancer therapies such as surgery, chemotherapy, and radiotherapy. PDT comprises the administration of a photosensitizer, its accumulation in tumor tissue, and subsequent irradiation of the photosensitizer-loaded tumor, leading to the localized photoproduction of reactive oxygen species (ROS). The resulting oxidative damage ultimately culminates in tumor cell death, vascular shutdown, induction of an antitumor immune response, and the consequent destruction of the tumor. However, the ROS produced by PDT also triggers a stress response that, as part of a cell survival mechanism, helps cancer cells to cope with the PDT-induced oxidative stress and cell damage. These survival pathways are mediated by the transcription factors activator protein 1 (AP-1), nuclear factor E2-related factor 2 (NRF2), hypoxia-inducible factor 1 (HIF-1), nuclear factor κB (NF-κB), and those that mediate the proteotoxic stress response. The survival pathways are believed to render some types of cancer recalcitrant to PDT and alter the tumor microenvironment in favor of tumor survival. In this review, the molecular mechanisms are elucidated that occur post-PDT to mediate cancer cell survival, on the basis of which pharmacological interventions are proposed. Specifically, pharmaceutical inhibitors of the molecular regulators of each survival pathway are addressed. The ultimate aim is to facilitate the development of adjuvant intervention strategies to improve PDT efficacy in recalcitrant solid tumors.

20 June 2016 in Nanoscale
Verified
Journal Article
Closed access
PDF file
GOGirgis Obaid
Girgis Obaid
Mans BroekgaardenMans Broekgaarden
Mans Broekgaarden
Anne-Laure BulinAnne-Laure Bulin
Anne-Laure Bulin
HHHuang-Chiao Huang
Huang-Chiao Huang
JKJerrin Kuriakose
Jerrin Kuriakose
THTayyaba Hasan
Tayyaba Hasan
As clinical nanomedicine has emerged over the past two decades, phototherapeutic advancements using nanotechnology have also evolved and impacted disease management.


1 November 2019 in Biomaterials
Verified
Journal Article
Closed access
Mans BroekgaardenMans Broekgaarden
Mans Broekgaarden
SASriram Anbil
Sriram Anbil
Anne-Laure BulinAnne-Laure Bulin
Anne-Laure Bulin
GOGirgis Obaid
Girgis Obaid
ZMZhiming Mai
Zhiming Mai
THTayyaba Hasan
Tayyaba Hasan

7 September 2020 in Advanced Science
Verified
Journal Article
Open access
PDF file
Anne-Laure BulinAnne-Laure Bulin
Anne-Laure Bulin
Mans BroekgaardenMans Broekgaarden
Mans Broekgaarden
FCFrédéric Chaput
Frédéric Chaput
VBVictor Baisamy
Victor Baisamy
JGJan Garrevoet
Jan Garrevoet
HEHélène Elleaume
Hélène Elleaume
To improve the prognosis of glioblastoma, innovative radiotherapy regimens are required to augment the effect of tolerable radiation doses while sparing surrounding tissues. In this context, nanoscintillators are emerging radiotherapeutics that down‐convert X‐rays into photons with energies ranging from UV to near‐infrared. During radiotherapy, these scintillating properties amplify radiation‐induced damage by UV‐C emission or photodynamic effects. Additionally, nanoscintillators that contain high‐Z elements are likely to induce another, currently unexplored effect: radiation dose‐enhancement. This phenomenon stems from a higher photoelectric absorption of orthovoltage X‐rays by high‐Z elements compared to tissues, resulting in increased production of tissue‐damaging photo‐ and Auger electrons. In this study, Geant4 simulations reveal that rare‐earth composite LaF3:Ce nanoscintillators effectively generate photo‐ and Auger‐electrons upon orthovoltage X‐rays. 3D spatially resolved X‐ray fluorescence microtomography shows that LaF3:Ce highly concentrates in microtumors and enhances radiotherapy in an X‐ray energy‐dependent manner. In an aggressive syngeneic model of orthotopic glioblastoma, intracerebral injection of LaF3:Ce is well tolerated and achieves complete tumor remission in 15% of the subjects receiving monochromatic synchrotron radiotherapy. This study provides unequivocal evidence for radiation dose‐enhancement by nanoscintillators, eliciting a prominent radiotherapeutic effect. Altogether, nanoscintillators have invaluable properties for enhancing the focal damage of radiotherapy in glioblastoma and other radioresistant cancers.